Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPA-BP: Effect of dapagliflozin on flow-mediated dilation and blood pressure in hypertensive patients with controlled type 2 diabetes
2015-004164-11Phase 3Completed
- Sponsor
- Azienda Ospedaliero-Universitaria Pisana
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dapagliflozin in hypertension (HTN) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Azienda Ospedaliero-Universitaria Pisana. Primary endpoint: Change in brachial artery flow-mediated dilation after 4 weeks. Started Feb 2019; status: completed.
02
Drugs
dapagliflozin
03
Conditions
hypertension (HTN)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2015-004164-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004164-11.